First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR in Patients with BRAF V600E-mutated mCRC By Ogkologos - February 17, 2025 943 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma MOST POPULAR How CRISPR is Changing Cancer Research and Treatment July 27, 2020 Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response July 15, 2022 Blood test could tailor treatment after surgery July 14, 2021 Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 Load more HOT NEWS Children’s Hospital Lets Kids Ride Toy Cars Into Surgery To Ease... Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response EMA Recommends Granting a Marketing Authorisation for Ivosidenib Strengthening EU Support for Rare Cancers under the 2028–2034 Multiannual Financial...
